Clinical and Humanistic Outcomes of Pharmaceutical Care Interventions for Type 2 Diabetes Patients: A Randomized Controlled Trial.

Not Applicable

• Conditions: Circulatory System; Nutritional, Metabolic, Endocrine; Cardiology

• Registration Number: PACTR202311849462910
• Lead Sponsor: Federal Medical Centre Abakaliki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-05
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Ambulatory patients with a confirmed diagnosis of type 2 diabetes mellitus.
2. Patients on oral hypoglycemic therapy for over 6 months.
3. Patients resident within Abakaliki capital territory.
4. Patients with functional mobile phone numbers.
5. Patients who consented to the study orally.

Exclusion Criteria

1. Patients who are pregnant.
2. Patients with secondary forms of hypertension.
3. Patients below 30 years.
4. Patients resident outside the Abakaliki Capital Territory urban settlement.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary clinical outcome measures chosen were a reduction in Glycated Haemoglobin A1c and Fasting Blood Glucose levels at the end of the study. The primary humanistic outcome measure chosen was improvement in the physical and mental domain scores of the short form - 12 health-related quality of life questionnaire at the end of the study.

Secondary Outcome Measures

Name	Time	Method
Reductions in systolic blood pressure, diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, triglycerides, 10-year risk of coronary heart disease and body mass index, as well as, an increase in high-density lipoprotein cholesterol, increase in the percentage of drug therapy problems identified and resolved at the end of the study.